GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CASI Pharmaceuticals Inc (NAS:CASI) » Definitions » Pretax Margin %

CASI Pharmaceuticals (CASI Pharmaceuticals) Pretax Margin % : -86.88% (As of Dec. 2023)


View and export this data going back to 1996. Start your Free Trial

What is CASI Pharmaceuticals Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. CASI Pharmaceuticals's Pre-Tax Income for the three months ended in Dec. 2023 was $-5.97 Mil. CASI Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $6.87 Mil. Therefore, CASI Pharmaceuticals's pretax margin for the quarter that ended in Dec. 2023 was -86.88%.

The historical rank and industry rank for CASI Pharmaceuticals's Pretax Margin % or its related term are showing as below:

CASI' s Pretax Margin % Range Over the Past 10 Years
Min: -109175   Med: -313.79   Max: -77.61
Current: -77.61


CASI's Pretax Margin % is ranked better than
57.49% of 1028 companies
in the Biotechnology industry
Industry Median: -155.98 vs CASI: -77.61

CASI Pharmaceuticals Pretax Margin % Historical Data

The historical data trend for CASI Pharmaceuticals's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CASI Pharmaceuticals Pretax Margin % Chart

CASI Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,098.09 -313.79 -118.81 -86.83 -77.61

CASI Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -108.23 -69.65 -102.39 -50.36 -86.88

Competitive Comparison of CASI Pharmaceuticals's Pretax Margin %

For the Biotechnology subindustry, CASI Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CASI Pharmaceuticals's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where CASI Pharmaceuticals's Pretax Margin % falls into.



CASI Pharmaceuticals Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

CASI Pharmaceuticals's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-26.292/33.879
=-77.61 %

CASI Pharmaceuticals's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-5.972/6.874
=-86.88 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CASI Pharmaceuticals  (NAS:CASI) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


CASI Pharmaceuticals Pretax Margin % Related Terms

Thank you for viewing the detailed overview of CASI Pharmaceuticals's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


CASI Pharmaceuticals (CASI Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
9620 Medical Center Drive, Suite 300, Rockville, MD, USA, 20850
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world.
Executives
James Huang director 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Wei-wu He director, 10 percent owner, officer: Chairman and CEO ENTREMED, INC., 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Weihao Xu officer: Chief Financial Officer 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Larry Zhang officer: President 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Shrotriya Rajesh C Md director 157 TECHNOLOGY DRIVE, IRVINE CA 92618
Salisbury Franklin Cary Jr director 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Yue Alexander Wu director C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121
Wealth Strategy Holding Ltd 10 percent owner LEVEL 12, INTERNATIONAL COMMERCE CENTRE, 1 AUSTIN ROAD WEST, HONG KONG K3 HK
Alexander A Zukiwski officer: Chief Medical Officer 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
George Chi officer: Chief Financial Officer 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Dapeng Li 10 percent owner BUILDING 1037,XIHU GOLF,, ZHIGANG ROAD 200, HANGZHOU, ZHEJANG F4 310008
Idg-accel China Growth Fund Iii L.p. 10 percent owner UNIT 5505, 55TH FLOOR, THE CENTER, 99 QUEEN'S ROAD K3 00000
Spectrum Pharmaceuticals Inc 10 percent owner 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Sparkle Byte Ltd 10 percent owner P.O. BOX 957, OFFSHORE INCORPORATIONS CENTRE ROAD TOWN, TORTOLA D8 00000
Ken Ren director, officer: CEO and Director 3RD FL, BOROUGH A, BLOCK A, NO. 181 SOUTH TAIBAI ROAD, XI'AN, SHAANXI PROVINCE F4 710065